ALFINOR Tablet Ref.[28109] Active ingredients: Betahistine

Source: Υπουργείο Υγείας (CY)  Revision Year: 2014  Publisher: MEDOCHEMIE LTD, 1-10 Constantinoupoleos street, 3011 Limassol, Cyprus

4.1. Therapeutic indications

Betahistine dihydrochloride is indicated for:

  • vertigo,
  • tinnitus and hearing loss associated with Ménière’s syndrome.

4.2. Posology and method of administration

Posology

Adults

The initial dose is 8 to 16 mg three times daily, taken preferably with meals. Maintenance doses are generally in the range of 24 to 48 mg daily.

Elderly

No dosage adjustment is necessary.

Paediatric population

There are no dosage recommendations for children.

Method of administration

Betahistine tablets are administered orally.

4.9. Overdose

There is no specific antidote for betahistine. The patient should undergo gastric lavage. Symptomatic treatment is recommended.

6.3. Shelf life

36 months.

6.4. Special precautions for storage

Stored below 25°C in the original package, to protect from light and moisture.

6.5. Nature and contents of container

Alfinor tablets are packed into PVC-Aluminum blisters.

Boxes of 100 tablets (10 PVC-Al blisters x 10 tablets).

6.6. Special precautions for disposal and other handling

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.